You have full text access to this OnlineOpen article

EAACI/GA2LEN/EDF guideline: management of urticaria

  1. T. Zuberbier1,
  2. C. Bindslev-Jensen2,
  3. W. Canonica3,
  4. C. E. H. Grattan4,
  5. M. W. Greaves5,
  6. B. M. Henz1,
  7. A. Kapp6,
  8. M. M. A. Kozel7,
  9. M. Maurer1,
  10. H. F. Merk8,
  11. T. Schäfer9,
  12. D. Simon10,
  13. G. A. Vena11,
  14. B. Wedi6

Article first published online: 17 NOV 2005

DOI: 10.1111/j.1398-9995.2005.00962.x

Issue

Allergy

Allergy

Volume 61, Issue 3, pages 321–331, March 2006

Additional Information

How to Cite

Zuberbier, T., Bindslev-Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., Maurer, M., Merk, H. F., Schäfer, T., Simon, D., Vena, G. A. and Wedi, B. (2006), EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy, 61: 321–331. doi: 10.1111/j.1398-9995.2005.00962.x

Author Information

  1. 1

    Department of Dermatology and Allergy, Charité– Universitätsmedizin Berlin, Berlin, Germany

  2. 2

    Allergy Centre, Department of Dermatology, Odense University Hospital, Odense, Denmark

  3. 3

    Allergy and Respiratory Diseases, DIMI – University of Genoa, Genoa, Italy

  4. 4

    Dermatology Centre, Norfolk and Norwich University Hospital, Norwich, UK

  5. 5

    Department of Dermatology, Singapore General Hospital, Singapore

  6. 6

    Department of Dermatology and Allergology, Hannover Medical University, Hannover, Germany

  7. 7

    Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

  8. 8

    Department of Dermatology, University Hospital RWTH Aachen, Aachen, Germany

  9. 9

    Institute of Social Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany

  10. 10

    Department of Dermatology, University Hospital Bern, Bern, Switzerland

  11. 11

    Department MIDIM, Unit of Dermatology, University of Bari, Bari, Italy

*Prof. Dr T. Zuberbier Department of Dermatology and Allergy Allergy Centre Charité Charité Universitätsmedizin Berlin Campus Mitte Schumannstr. 20/21 D-10117 BerlinGermany

Publication History

  1. Issue published online: 23 JAN 2006
  2. Article first published online: 17 NOV 2005
  3. Accepted for publication 13 July 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (134K)

Keywords:

  • consensus;
  • SIGN;
  • treatment guideline;
  • urticaria;
  • wheal

This guideline is the result of a consensus reached during a panel discussion at the second International Consensus Meeting on Urticara, Urticaria 2004, a joint initiative of the EAACI Dermatology Section and GA2LEN. Urticaria has a profound impact on the quality of life, and effective treatment is therefore required. The recommended first line treatment are nonsedating H1 antihistamines. They have proven to be effective in double-blind controlled studies, but dosages increased up to fourfold over the recommended doses may be necessary. However, for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment, additional or alternative therapies may be required. Immunosuppressive drugs like cyclosporin A and corticosteroids are not recommended for long-term treatment due to unavoidable severe adverse effects. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and formally approved by the European Union of Medical Specialists (UEMS).

View Full Article (HTML) Get PDF (134K)